Published time: 29 April 2020
Authors: David Hudesman, M.D. Jose U. Scher, M.D.
Keywords: Immune-mediated, inflammatory diseases, case study, Covid-19.
Data on Covid-19 in patients with immune-mediated inflammatory disease who have received anticytokine biologics, other immunomodulatory therapies, or both on a long-term basis are scarce. Trials to assess the efficacy of antirheumatic therapies such as hydroxychloroquine1 and anticytokine therapies such as interleukin-6 inhibitors2 to improve outcomes in patients with Covid-19 are ongoing. The rationale for their use is that worse outcomes (i.e., hospitalization, ventilation, or death) may be related to a proinflammatory cytokine storm.
Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York